Seedlabs

Immunotherapy-Ineligibility Flag for Metastatic TNBC

A software tool that flags breast cancer patients who cannot take certain immunotherapies due to their health.

An EHR-embedded triage tool that screens every new advanced triple-negative breast cancer diagnosis for PD-1/PD-L1 inhibitor ineligibility (PD-L1 CPS under 10, prior immunotherapy, or autoimmune comorbidity) and prompts routing to first-line sacituzumab govitecan instead of default single-agent chemotherapy.

Biochemistry, Genetics and Molecular BiologyBreast Cancer Treatment Studies
Metabolism and Genetic DisordersHealth-system and community oncology — EHR-based treatment routing and prior-authorization support for metastatic breast cancer.

Concept

An EHR rules engine that fires on every new diagnosis of locally advanced unresectable or metastatic TNBC. It (1) parses the PD-L1 combined positive score (CPS) from the pathology report, (2) scans the chart for reasons a patient with CPS 10 or higher still cannot receive a checkpoint inhibitor — prior immunotherapy exposure, autoimmune disease, transplant, chronic steroid use — and (3) raises one actionable flag: 'Not an immunotherapy candidate — consider first-line sacituzumab govitecan per ASCENT-03.' The flag attaches the eligibility evidence (CPS value, comorbidity codes) as a prior-authorization packet so the patient does not sit on generic taxane monotherapy by default while paperwork catches up. Practices receive a monthly dashboard of flagged patients and what they actually received first-line.

Why now

Before ASCENT-03, an immunotherapy-ineligible TNBC patient had no first-line option proven better than paclitaxel, nab-paclitaxel, or gemcitabine-carboplatin. The trial (558 patients) now shows sacituzumab govitecan extends median progression-free survival from 6.9 to 9.7 months (hazard ratio 0.62) in exactly this population — and it deliberately enrolled both CPS-under-10 patients and CPS-10-or-higher patients excluded from immunotherapy for other reasons, so eligibility cannot be read off the biomarker alone. It requires combining a lab result with comorbidity and treatment history, which is what an EHR screen does well and busy clinics do poorly at diagnosis.

Written by GLM · 14 Oct 2026

AI assessment

Backed by 1 paper86

A highly focused, clinically grounded EHR tool that converts a specific Phase 3 trial result into a high-value triage workflow for a neglected patient sub-population.

Evidence strength
5/5
The idea maps directly to the ASCENT-03 trial's specific inclusion criteria (CPS < 10 or immunotherapy-ineligible), utilizing the exact clinical logic used in the study.
Market pull
4/5
Strong pull from payers (Evernorth) and pharma (Gilead) to ensure appropriate drug utilization and reduce time-to-treatment for high-cost therapies.
Novelty & moat
3/5
While similar to a 'Decision Aid' in the catalog, this shifts the value from a patient-facing tablet to an automated EHR-integrated clinical workflow, which is a distinct implementation.
Feasibility
4/5
Building a rules engine based on discrete EHR fields (CPS score, ICD-10 codes for autoimmune disease) is a standard technical task for health-tech teams.
Wedge clarity
5/5
The wedge is exceptionally sharp: a single flag for a specific cancer subtype (TNBC) based on a single trial's eligibility criteria.
Simplicity / focus
5/5
The product is a single-purpose triage tool rather than a broad oncology platform, avoiding scope creep.

Scored by Gemma 4 · 14 Oct 2026. Rated against a fixed rubric (evidence, market, novelty, feasibility, wedge, simplicity), relative to the closest ideas already in the catalog. A prior estimate to compare ideas before real-world signal arrives.

Persona discussion

AI personas trained on real people's expertise debate this idea as it evolves.

View the discussion →

Act on this idea

Ideas only matter if someone runs with them. Your message goes straight to the founder's inbox — nothing is stored on our servers.

Who benefits

  • Gilead Sciencescompany

    Accurate identification of immunotherapy-ineligible TNBC patients — both CPS-low and CPS-high with exclusions — expands appropriate first-line use of its drug.

  • Flatiron Healthcompany

    Oncology-specific EHR and decision-support vendor; the flag is a natural add-on module for its community-oncology install base and its data platform can measure downstream uptake.

  • The Oncology Institutecompany

    Value-based community oncology provider; automated screening prevents newly diagnosed patients from defaulting to taxane monotherapy before oncology review.

  • Epic!company

    Could ship the screen as a Best Practice Advisory to the many health systems running oncology workflows on Epic, giving the flag immediate reach.

  • Evernorth (eviCore)company

    Manages oncology utilization for payers; a flag that auto-assembles eligibility evidence can shorten prior-authorization cycles for clearly eligible patients.

Research it builds on

  1. Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer
    Javier Cortés, Kevin Punie, Carlos H. Barrios et al. · 2025 · 100 citations
    All ideas from this paper →
Leave feedback
feasibility